Drugs / ABC294640
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01488513 | Aug 2011 → Aug 2014 | malignant pancreatic neoplasm | RedHill Biopharma Limited | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04502069 | Aug 2020 → Feb 2021 | COVID-19, respiratory tract infectious disorder | RedHill Biopharma Limited | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02757326 | Dec 2016 → May 2019 | plasma cell myeloma | RedHill Biopharma Limited | Terminated | No outcome recorded |
| Phase 1/2 | NCT02229981 | Jul 2014 → Jun 2019 | Kaposi's sarcoma, diffuse large B-cell lymphoma | RedHill Biopharma Limited | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04207255 | Mar 2020 → Aug 2023 | prostate cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT02939807 | Sep 2019 → Sep 2023 | hepatocellular carcinoma | Medical University of South Carolina | Withdrawn | No outcome recorded |
| Phase 2 | NCT03377179 | Mar 2018 → Jun 2022 | hilar cholangiocarcinoma | RedHill Biopharma Limited | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04467840 | Aug 2020 → Jul 2021 | COVID-19, pneumonia | RedHill Biopharma Limited | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03414489 | — | hilar cholangiocarcinoma | RedHill Biopharma Limited | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04414618 Comparator | Jul → Nov 2020 | Coronaviridae infectious disease | RedHill Biopharma Limited | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABC294640 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03377179 ↗ |
| Known as | Opaganib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04414618 ↗ |
| Known as | Yeliva | “This program is designed to provide access to ABC294640 (Yeliva ®) for treatment of cholangiocarcinoma (CCA) prior to approval by the local regulatory agency.” NCT03414489 ↗ |
| Action | Inhibit | “sphingosine kinase-2 inhibitor ABC294640” NCT01488513 ↗ |
| Modality | Small molecule | — CHEMBL2158685 ↗ |
| Route | Oral | “Patients receive sphingosine kinase-2 inhibitor ABC294640 orally (PO) twice daily (BID) on days 1-28.” NCT01488513 ↗ |
| Target | SPHK2 | “selective SphK2 inhibition” NCT04414618 ↗ |